Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04920253 · ClinicalTrials.gov registry record · NA
Real World Evidence with the Debritom+ TM Novel Micro Water Jet Technology At a Single Wound Center
A NA study of Diabetic Foot Ulcer and Venous Leg Ulcer, sponsored by Medaxis.
- Recruiting
- Registry status
- NA
- Development phase
- 180
- Enrollment target
- 1
- Study location
NCT04920253: Recruiting NA study of Diabetic Foot Ulcer and Venous Leg Ulcer, sponsored by Medaxis.
NCT04920253 is a NA study of Diabetic Foot Ulcer and Venous Leg Ulcer that is actively recruiting participants, run by Medaxis. The registered enrollment target is 180 participants, below the 252-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (29% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04920253, a NA study of Diabetic Foot Ulcer and Venous Leg Ulcer, is actively recruiting participants, sponsored by Medaxis.
- RECRUITING
- Registry status
- NA
- Development phase
- 180 participants
- Enrollment target
- 1
- Study location
Study Summary
Prospective, single-blinded, single-center, parallel group, randomized controlled trial (RCT) to assess rate and frequency of wound healing and associated financial savings, when using Medaxis debritom+ versus standard of care as a choice of debridement method, where both arms follow normal wound care practice in use of advanced wound care treatments.
Primary Outcome
Time to heal
Conditions Studied
Interventions
- DEVICE Study Device Debridement
- DEVICE SOC Debridement
Study Locations (1)
Florida
- MCR Health, Inc. - Bradenton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2021-11-29 |
| Est. Completion | 2025-12 |
| Phase | NA |
What NCT04920253 shows while recruiting
NCT04920253 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 252-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (29% lower).
The record links to 4 conditions, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 2 interventions - of which Study Device Debridement is the first listed.
NCT04920253 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04920253 about?
NCT04920253 is a clinical study titled "Real World Evidence with the Debritom+ TM Novel Micro Water Jet Technology At a Single Wound Center". Prospective, single-blinded, single-center, parallel group, randomized controlled trial (RCT) to assess rate and frequency of wound healing and associated financial savings, when using Medaxis debritom+ versus standard of care as a choice of debridement method, where both arms follow normal wound ca...
What is the current status of trial NCT04920253?
This trial is currently recruiting. It is a NA study. The enrollment target is 180 participants. The study started on 2021-11-29. Estimated completion is 2025-12.
What conditions does trial NCT04920253 study?
This clinical trial studies the following conditions: Diabetic Foot Ulcer, Venous Leg Ulcer, Surgical Wound Dehiscence, Traumatic Wounds.
What interventions are being tested in trial NCT04920253?
The interventions under investigation include: Study Device Debridement (DEVICE), SOC Debridement (DEVICE).
Who is sponsoring clinical trial NCT04920253?
This trial is sponsored by Medaxis, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04920253 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Foot Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04920253's enrollment target sits among peer trials
180 19th of 67 higher than 48 of 67 other Diabetic Foot Ulcer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Foot Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot Ulcers
RECRUITING · NA
-
Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating DFU and SanoGraft® in Treating VLU to SOC
RECRUITING · NA
-
A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.
RECRUITING · NA
-
Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs
RECRUITING · NA
-
Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone
RECRUITING · NA
-
Exercise Enhances Wound Healing in Patients With Diabetic Foot Ulcers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI